Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
$1.37
-8.7%
$1.65
$1.33
$5.00
$3.59M1.888,579 shs19,761 shs
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
$0.08
$0.49
$0.05
$23.40
$407K1.31.36 million shs23,154 shs
Nephros, Inc. stock logo
NEPH
Nephros
$2.19
$2.49
$1.13
$4.04
$23.08M1.318,975 shs4,904 shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
-1.76%+6.22%-14.11%-16.50%-61.92%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
+3.90%+14.29%-81.47%-91.95%-99.34%
Nephros, Inc. stock logo
NEPH
Nephros
0.00%+10.05%-0.90%-38.83%+51.06%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
1.6454 of 5 stars
3.53.00.00.01.90.00.6
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
1.38 of 5 stars
3.53.00.00.01.10.00.6
Nephros, Inc. stock logo
NEPH
Nephros
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
3.00
Buy$10.00629.93% Upside
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
3.00
Buy$28.8835,548.15% Upside
Nephros, Inc. stock logo
NEPH
Nephros
N/AN/AN/AN/A

Current Analyst Ratings

Latest AEMD, NEPH, and MOTS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/4/2024
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$23.00 ➝ $10.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
$570K6.30N/AN/A$6.56 per share0.21
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
$320K1.27N/AN/A$1.74 per share0.05
Nephros, Inc. stock logo
NEPH
Nephros
$14.24M1.62N/AN/A$0.80 per share2.74

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
-$12.03M-$4.99N/AN/AN/AN/A-106.28%-86.60%6/26/2024 (Estimated)
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
-$12.87M-$28.55N/AN/A-4,033.54%N/A-110.70%5/8/2024 (Estimated)
Nephros, Inc. stock logo
NEPH
Nephros
-$1.58M-$0.15N/AN/A-11.06%-18.25%-14.29%5/8/2024 (Estimated)

Latest AEMD, NEPH, and MOTS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/18/2024Q4 2023
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
N/A-$4.13-$4.13-$3.78N/A$0.06 million
3/7/2024Q4 2023
Nephros, Inc. stock logo
NEPH
Nephros
N/A-$0.06-$0.06-$0.06N/A$3.25 million    
2/14/2024Q3 2024
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
-$1.23-$1.37-$0.14-$1.37N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
N/AN/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
N/AN/AN/AN/AN/A
Nephros, Inc. stock logo
NEPH
Nephros
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
N/A
3.93
3.93
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
0.46
1.76
1.69
Nephros, Inc. stock logo
NEPH
Nephros
N/A
3.98
2.81

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
1.99%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
20.06%
Nephros, Inc. stock logo
NEPH
Nephros
41.10%

Insider Ownership

CompanyInsider Ownership
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
4.00%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
1.57%
Nephros, Inc. stock logo
NEPH
Nephros
4.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
152.62 million2.52 millionNo Data
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
155.03 million4.95 millionNot Optionable
Nephros, Inc. stock logo
NEPH
Nephros
3110.54 million10.11 millionNot Optionable

AEMD, NEPH, and MOTS Headlines

SourceHeadline
How to beat Nephro, Captain of the Guard in Another Crab’s TreasureHow to beat Nephro, Captain of the Guard in Another Crab’s Treasure
pcinvasion.com - April 26 at 4:42 PM
Nephros to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024Nephros to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
finance.yahoo.com - April 23 at 8:26 AM
Nephros, Inc. (NEPH) Interactive Stock Chart - Yahoo FinanceNephros, Inc. (NEPH) Interactive Stock Chart - Yahoo Finance
finance.yahoo.com - April 20 at 2:20 PM
Nephros, Inc.s (NASDAQ:NEPH) Profit OutlookNephros, Inc.'s (NASDAQ:NEPH) Profit Outlook
finance.yahoo.com - April 19 at 2:44 PM
Nephros (NASDAQ:NEPH)  Shares Down 0.5% Nephros (NASDAQ:NEPH) Shares Down 0.5%
americanbankingnews.com - April 16 at 1:52 AM
Nephros, Inc.: Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsNephros, Inc.: Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results
finanznachrichten.de - March 11 at 11:49 PM
Nephros Full Year 2023 Earnings: Misses ExpectationsNephros Full Year 2023 Earnings: Misses Expectations
finance.yahoo.com - March 10 at 9:26 AM
Nephros Poised for Growth: A Buy Recommendation Amid Expansion and Optimized OperationsNephros Poised for Growth: A Buy Recommendation Amid Expansion and Optimized Operations
markets.businessinsider.com - March 9 at 7:27 PM
Nephros Poised for Growth: Strong Financials and Strategic Initiatives Secure Buy RatingNephros Poised for Growth: Strong Financials and Strategic Initiatives Secure Buy Rating
markets.businessinsider.com - March 9 at 12:36 AM
Nephros just upgraded at Benchmark, heres whyNephros just upgraded at Benchmark, here's why
realmoney.thestreet.com - March 8 at 4:31 PM
Nephros, Inc. (NASDAQ:NEPH) Q4 2023 Earnings Call TranscriptNephros, Inc. (NASDAQ:NEPH) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 8 at 2:34 PM
NEPH Stock Earnings: Nephros Misses EPS, Misses Revenue for Q4 2023NEPH Stock Earnings: Nephros Misses EPS, Misses Revenue for Q4 2023
msn.com - March 7 at 10:44 PM
Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsNephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results
globenewswire.com - March 7 at 4:15 PM
Earnings Outlook For NephrosEarnings Outlook For Nephros
benzinga.com - March 6 at 4:41 PM
Nephros earnings: heres what to expectNephros earnings: here's what to expect
markets.businessinsider.com - March 6 at 4:41 PM
Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial ResultsNephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results
globenewswire.com - February 29 at 4:30 PM
Point-of-Use Filter Market Analysis With Top Key Players, Applications, And Trends During The Forecast PeriodPoint-of-Use Filter Market Analysis With Top Key Players, Applications, And Trends During The Forecast Period
opprairie.com - February 12 at 10:38 AM
What Is Nephros, Inc.s (NASDAQ:NEPH) Share Price Doing?What Is Nephros, Inc.'s (NASDAQ:NEPH) Share Price Doing?
finance.yahoo.com - January 28 at 9:53 AM
Rezolute, Inc.: Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial OfficerRezolute, Inc.: Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
finanznachrichten.de - January 24 at 1:41 PM
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial OfficerRezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
finance.yahoo.com - January 24 at 8:40 AM
Nephros, Inc.s (NASDAQ:NEPH) P/S Is Still On The Mark Following 40% Share Price BounceNephros, Inc.'s (NASDAQ:NEPH) P/S Is Still On The Mark Following 40% Share Price Bounce
finance.yahoo.com - December 18 at 8:54 AM
Nephros Inc NEPHNephros Inc NEPH
morningstar.com - December 14 at 12:08 AM
Are Investors Undervaluing Nephros, Inc. (NASDAQ:NEPH) By 45%?Are Investors Undervaluing Nephros, Inc. (NASDAQ:NEPH) By 45%?
finance.yahoo.com - December 13 at 6:29 AM
Nephros CEO buys 18k shares of the company - filingNephros CEO buys 18k shares of the company - filing
msn.com - December 12 at 5:38 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aethlon Medical logo

Aethlon Medical

NASDAQ:AEMD
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.
Motus GI logo

Motus GI

NASDAQ:MOTS
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.
Nephros logo

Nephros

NASDAQ:NEPH
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.